Ruiming New Medicine has completed nearly 100 million yuan in A+ round of financing: promote project IND declaration and new project introduction

Recently, the leading domestic therapeutic small molecule ophthalmic new drug research and development platform, Suzhou Ruiming New Drug Research and Development Co.

The company has a world-leading medicinal chemistry design platform in the field of drug penetration and treatment of ocular diseases, especially fundus disease tissues

At present, the company's product pipeline covers all areas of ophthalmic vascular and neurological diseases.

Adhering to the concept of "science and technology for health", the company strives to further expand new pipelines in the areas of unmet needs in the target market, so as to achieve the role of curing ophthalmic diseases, promote the development of innovative ophthalmic drugs, and bring light and hope to patients

Luo Rushu, managing partner of Huimei Capital, said:

The treatment of fundus diseases with eye drops is the "crown" of drug treatment of fundus diseases

Dr.

Under the aging trend of the global society, ophthalmology, especially fundus diseases, is one of the medical markets with the most rigid market demand and development potential

Dr.

Suzhou Ruiming focuses on innovative therapeutic small-molecule ophthalmic drugs, has an international team and differentiated R&D strategies.

About Huimei Capital

HM Capital is a vertical fund focusing on healthcare investment in Hillhouse Capital Group's ecology.

About Taiyu Investment

Taiyu Investment was established in 2014 and is an independent professional venture capital institution under the listed company Tigermed

About Shengding Pharmaceutical Investment

Shengding Pharmaceutical Investment is a professional venture capital institution with a background in the medical industry, focusing on investing and establishing potential innovative companies in the life sciences and medical and health fields on a global scale